1|Page
ABSITE EXAM COMPLETE 200 QUESTIONS AND CORRECT
SOLUTIONS LATEST 2024-2025
QUESTION: Immunohistochemical stain that differentiates Epithelioid hemangioendothelioma
from other nonvascular tumors? - ANSWER-Factor VII
QUESTION: Best predictor of long-term success in patients with TBI - ANSWER-Post-
resuscitation GCS (not initial)
QUESTION: Cardiac allograft rejection - ANSWER-Usually asymptomatic, steroid treatment in
first 3 months of rejection
T-cell mediated
QUESTION: Pathophysiology behind refeeding syndrome - ANSWER-Sudden influx of phosphate
into cells triggered by the resumption of adenosine triphosphate production, which results in
hypophosphatemia.
QUESTION: Pneumobilia vs. portal venous gas - ANSWER-Pneumobilia: Central
Portal venous gas: Peripheral
QUESTION: Immunosuppressive agent with the highest rate of post-transplant new onset
diabetes - ANSWER-Tacrolimus
MC model for the dissemination and implementation of evidence-based best practices -
ANSWER-RE-AIM
QUESTION: Adjustment for trough being too high - ANSWER-DECREASE frequency of
administered antibiotic (increase time between dosing)
,2|Page
QUESTION: MC organism in SBP - ANSWER-E.coli (usually monomicrobial)
If polymicrobial, concern for perforated viscus
QUESTION: MCC of benign biliary stricture - ANSWER-Previous cholecystectomy
QUESTION: Primary lymphoid organs - ANSWER-"The Best Lymphoid" Thymus, Bone, Liver
QUESTION: Treatment for SCC of proximal esophagus - ANSWER-Definitive chemoradiation
QUESTION: Adrenal-lytic used for recurrent, residual, or metastatic disease - ANSWER-Mitotane
QUESTION: Hypomagnesemia can led to which electrolyte deficiencies - ANSWER-Hypokalemia
and hypocalcemia
QUESTION: Treatment of ventral hernia in dialysis patients about to get PD catheter placed -
ANSWER-Repair hernia with extraperitoneal mesh and place PD catheter at same time
QUESTION: MC malignant tumor of the small bowel - ANSWER-Mets from another primary
(MELANOMA)
QUESTION: MC primary malignant tumor of the small bowel - ANSWER-Adenocarcinoma (rare)
QUESTION: Medical management for patients with desmoid tumors with high risk or have high
morbidity if managed surgically, such as those involving the mesentery, major vessels, or other
critical structures - ANSWER-NSAIDs and Tamoxifen
QUESTION: Initiating event in the formation of ascites - ANSWER-Sinusoidal portal hypertension
, 3|Page
QUESTION: Antibiotic re-dosing for colon procedures - ANSWER-Re-dose if > 2 hours or if
significant blood loss
QUESTION: Surgical management of duodenal tumors less than 1 cm in diameter - ANSWER-
Endoscopic polypectomy
QUESTION: VTE prophylaxis in patients undergoing major abdominal/pelvic operations for
cancer - ANSWER-Subcutaneous LMWH for 28 days
QUESTION: Work-up for children with cervical lymphadenopathy - ANSWER-< 2cm: 2 week
follow up if non-tender, mobile
>/= 2cm: CBC, ESR, CRP, CXR
- If concerning features -> biopsy
- If not, 10-14 days abx with follow up
QUESTION: Primary cancer most likely to mets to the adrenal glands - ANSWER-Lung
QUESTION: Reversal of Clopidogrel - ANSWER-Transfused pooled platelets, Desmopressin
QUESTION: Which immunotherapy agent targets PD-L1 and what caner is it used for? -
ANSWER-Pembrolizumab, NSCLC
QUESTION: Which immunotherapy agent targets RET and what caner is it used for? - ANSWER-
Selpercatinib, medullary thyroid cancer in MEN 2A/2B
QUESTION: Which immunotherapy agent targets CTLA-4 and what caner is it used for? -
ANSWER-Ipilimumab, Melanoma
ABSITE EXAM COMPLETE 200 QUESTIONS AND CORRECT
SOLUTIONS LATEST 2024-2025
QUESTION: Immunohistochemical stain that differentiates Epithelioid hemangioendothelioma
from other nonvascular tumors? - ANSWER-Factor VII
QUESTION: Best predictor of long-term success in patients with TBI - ANSWER-Post-
resuscitation GCS (not initial)
QUESTION: Cardiac allograft rejection - ANSWER-Usually asymptomatic, steroid treatment in
first 3 months of rejection
T-cell mediated
QUESTION: Pathophysiology behind refeeding syndrome - ANSWER-Sudden influx of phosphate
into cells triggered by the resumption of adenosine triphosphate production, which results in
hypophosphatemia.
QUESTION: Pneumobilia vs. portal venous gas - ANSWER-Pneumobilia: Central
Portal venous gas: Peripheral
QUESTION: Immunosuppressive agent with the highest rate of post-transplant new onset
diabetes - ANSWER-Tacrolimus
MC model for the dissemination and implementation of evidence-based best practices -
ANSWER-RE-AIM
QUESTION: Adjustment for trough being too high - ANSWER-DECREASE frequency of
administered antibiotic (increase time between dosing)
,2|Page
QUESTION: MC organism in SBP - ANSWER-E.coli (usually monomicrobial)
If polymicrobial, concern for perforated viscus
QUESTION: MCC of benign biliary stricture - ANSWER-Previous cholecystectomy
QUESTION: Primary lymphoid organs - ANSWER-"The Best Lymphoid" Thymus, Bone, Liver
QUESTION: Treatment for SCC of proximal esophagus - ANSWER-Definitive chemoradiation
QUESTION: Adrenal-lytic used for recurrent, residual, or metastatic disease - ANSWER-Mitotane
QUESTION: Hypomagnesemia can led to which electrolyte deficiencies - ANSWER-Hypokalemia
and hypocalcemia
QUESTION: Treatment of ventral hernia in dialysis patients about to get PD catheter placed -
ANSWER-Repair hernia with extraperitoneal mesh and place PD catheter at same time
QUESTION: MC malignant tumor of the small bowel - ANSWER-Mets from another primary
(MELANOMA)
QUESTION: MC primary malignant tumor of the small bowel - ANSWER-Adenocarcinoma (rare)
QUESTION: Medical management for patients with desmoid tumors with high risk or have high
morbidity if managed surgically, such as those involving the mesentery, major vessels, or other
critical structures - ANSWER-NSAIDs and Tamoxifen
QUESTION: Initiating event in the formation of ascites - ANSWER-Sinusoidal portal hypertension
, 3|Page
QUESTION: Antibiotic re-dosing for colon procedures - ANSWER-Re-dose if > 2 hours or if
significant blood loss
QUESTION: Surgical management of duodenal tumors less than 1 cm in diameter - ANSWER-
Endoscopic polypectomy
QUESTION: VTE prophylaxis in patients undergoing major abdominal/pelvic operations for
cancer - ANSWER-Subcutaneous LMWH for 28 days
QUESTION: Work-up for children with cervical lymphadenopathy - ANSWER-< 2cm: 2 week
follow up if non-tender, mobile
>/= 2cm: CBC, ESR, CRP, CXR
- If concerning features -> biopsy
- If not, 10-14 days abx with follow up
QUESTION: Primary cancer most likely to mets to the adrenal glands - ANSWER-Lung
QUESTION: Reversal of Clopidogrel - ANSWER-Transfused pooled platelets, Desmopressin
QUESTION: Which immunotherapy agent targets PD-L1 and what caner is it used for? -
ANSWER-Pembrolizumab, NSCLC
QUESTION: Which immunotherapy agent targets RET and what caner is it used for? - ANSWER-
Selpercatinib, medullary thyroid cancer in MEN 2A/2B
QUESTION: Which immunotherapy agent targets CTLA-4 and what caner is it used for? -
ANSWER-Ipilimumab, Melanoma
